NORDITROPIN FLEXPRO 15 MG / 1.5 ML — DIN 02529211
NORDITROPIN FLEXPRO · NOVO NORDISK CANADA INC · wholesale supply in Canada
Health Canada status: MARKETED
What is NORDITROPIN FLEXPRO?
NORDITROPIN FLEXPRO 15 MG / 1.5 ML contains NORDITROPIN FLEXPRO. It is listed in the Health Canada Drug Product Database under DIN 02529211, held by NOVO NORDISK CANADA INC. Health Canada currently lists it as marketed, status dated 07-Dec-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NORDITROPIN FLEXPRO used for?
Pediatric growth failure due to GHD; growth disturbance in children born small for gestational age (SGA); short stature associated with Turner syndrome or Noonan syndrome.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 15 MG / 1.5 ML |
|---|---|
| Pack configuration (monograph) | 5 mg/1.5 mL, 10 mg/1.5 mL, and 15 mg/1.5 mL pre-filled pens individually packaged in a carton. |
| Storage | Not explicitly detailed in provided text snippet (refer to section 11 in full monograph). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02529211 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2529211 |
| Brand name | NORDITROPIN FLEXPRO |
| Generic / active ingredient | NORDITROPIN FLEXPRO |
| Market authorization holder | NOVO NORDISK CANADA INC |
| Health Canada schedule | PRESCRIPTION |
| Current status | MARKETED |
| Status date | 07-Dec-2022 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Subcutaneous injection, usually daily in the evening. Rotate sites. Dosage individualized by weight and indication (GHD: up to 0.043 mg/kg/day; SGA/Turner: up to 0.067 mg/kg/day).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; acute critical illness; Prader-Willi syndrome with severe obesity/respiratory impairment; active neoplasm; closed epiphyses; diabetic retinopathy; renal transplantation.
Warnings and precautions
Increased mortality in acute critical illness; fatalities reported in Prader-Willi syndrome; risk of secondary neoplasms in cancer survivors; monitor for intracranial hypertension and scoliosis.
Is NORDITROPIN FLEXPRO in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Discontinued — reported by NOVO NORDISK CANADA INC, last seen 12 Mar 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.